Status message

Active context: kki_bg_colors_yellow

A 6-Month Study to Evaluate the Safety, Tolerability and Efficacy of Desvenlafaxine Succinate Sustained-Release (Dvs Sr) Tablets in the Treatment of Children and Adolescent Outpatients with Major Depressive Disorder

Principal Investigator:
Robert
Findling

A 6-Month, Open-Label, Multi-Center, Flexible-Dose Extension Study to the B2061032 Study to Evaluate the Safety, Tolerability and Efficacy of Desvenlafaxine Succinate Sustained-Release (Dvs Sr) Tablets in the Treatment of Children and Adolescent Outpatients with Major Depressive Disorder

To evaluate the long-term safety and tolerability of DVS SR in the treatment of children and adolescents with MDD.

Publications

Read inspiring stories, news and updates about the Institute's patient care, research, special education, professional training, and community programs.